ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Chemotherapy induction regimens for acute promyelocytic leukemia

Chemotherapy induction regimens for acute promyelocytic leukemia
Drugs Dosing Comments
ATRA plus idarubicin[1] ATRA: 45 mg/m2 per day in two divided doses until complete response. This is the AIDA protocol that yields a 94 percent remission rate. After three intensive consolidation courses plus maintenance therapy, the event-free survival at 12 years was 69 percent.
Idarubicin: 12 mg/m2 intravenous push days 2, 4, 6, and 8.
ATRA plus daunorubicin plus cytarabine[2] ATRA: 45 mg/m2 per day in two divided doses until complete response. This North American Intergroup regimen had a high complete remission rate of 90 percent. When followed by arsenic trioxide for consolidation, the event-free survival was 80 percent and overall survival 86 percent at three years. Disease-free survival was 90 percent.
Daunorubicin: 50 mg/m2 intravenous push on each of days 3 through 6 (four doses).
Cytarabine: 200 mg/m2 daily as a continuous infusion for days 3 through 9 (seven days).
ATRA plus arsenic trioxide[3] ATRA: 45 mg/m2 per day in two divided doses until complete response. Initial studies demonstrate good results with short follow-up. Yields a >85 percent remission rate. May be an excellent option for patients with low or intermediate risk disease, especially those who are not able to tolerate anthracycline-based therapy. Hydroxyurea, daunorubicin, or gemtuzumab ozogamicin have been added if the WBC count rises dramatically.
Arsenic trioxide: 0.15 mg/kg per day until complete response.
ATRA plus arsenic trioxide plus gemtuzumab ozogamicin[4] ATRA: 45 mg/m2 per day in two divided doses until complete response. Initial study demonstrated a response rate of 92 percent. At a median follow-up of 24 months, the estimated three-year survival rate was 85 percent. Disease-related complications resulted in an early death rate of 8 percent.
Arsenic trioxide: 0.15 mg/kg per day beginning on day 1 with the ATRA and continuing until complete response.
Gemtuzumab ozogamicin: 9 mg/m2 on day 1 for high risk patients (defined as white count ≥10x109/L).
ATRA: all-trans retinoic acid (tretinoin).
References:
  1. Avvisati G, Lo-Coco F, Paoloni FP, et al. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood 2011; 117:4716.
  2. Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 2010; 116:3751.
  3. Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013; 369:111.
  4. Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with All-Trans-Retinoic Acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 2009; 27:504.
Graphic 51345 Version 6.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟